Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19811
Title: Efficacy of cannabinoids in paediatric epilepsy.
Authors: Ali, Shayma;Scheffer, Ingrid E;Sadleir, Lynette G
Affiliation: The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia
Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand
Royal Children's Hospital, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Departments of Medicine and Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
Murdoch Children's Research Institutes, Melbourne, Victoria, Australia
Issue Date: 6-Nov-2018
EDate: 2018-11-06
Citation: Developmental medicine and child neurology 2018; online first: 6 November
Abstract: There are hundreds of compounds found in the marijuana plant, each contributing differently to the antiepileptic and psychiatric effects. Cannabidiol (CBD) has the most evidence of antiepileptic efficacy and does not have the psychoactive effects of ∆9 -tetrahydrocannabinol. CBD does not act via cannabinoid receptors and its antiepileptic mechanism of action is unknown. Despite considerable community interest in the use of CBD for paediatric epilepsy, there has been little evidence for its use apart from anecdotal reports, until the last year. Three randomized, placebo-controlled, double-blind trials in Dravet syndrome and Lennox-Gastaut syndrome found that CBD produced a 38% to 41% median reduction in all seizures compared to 13% to 19% on placebo. Similarly, CBD resulted in a 39% to 46% responder rate (50% convulsive or drop-seizure reduction) compared to 14% to 27% on placebo. CBD was well tolerated; however, sedation, diarrhoea, and decreased appetite were frequent. CBD shows similar efficacy to established antiepileptic drugs. WHAT THIS PAPER ADDS: Cannabidiol (CBD) shows similar efficacy in the severe paediatric epilepsies to other antiepileptic drugs. Careful down-titration of benzodiazepines is essential to minimize sedation with adjunctive CBD.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19811
DOI: 10.1111/dmcn.14087
ORCID: 0000-0002-9177-4938
0000-0002-2311-2174
0000-0002-5355-7115
PubMed URL: 30402932
Type: Journal Article
Review
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.